ABBOTT LABORATORIES — Director's Dealing 2019

Feb 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-02-22

Reporting Person: Funck Robert E (Senior Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-22	Common shares without par value	A	23344	—	Acquired	144673	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-22	Option (right to buy)	$75.90	A	122367	Acquired	2029-02-21	Common shares (122367)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	17297	Indirect
Common shares without par value	500	Indirect
Common shares without par value	500	Indirect

Footnotes

F1: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 22, 2019.

F3: The reporting person disclaims beneficial ownership of all securities held by his daughter.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 40,789 on February 22, 2020, 40,789 on February 22, 2021, and 40,789 on February 22, 2022.